Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

References

• RossJSFletcherJAThe HER-2/neu oncogene: prognostic factor, predictive factor and target for therapySemin Cancer Biol19999212513810202134
   PubMed Web of Science ®Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist200914432036819346299
   PubMed Web of Science ®Google Scholar
• BrowneBCO’BrienNDuffyMJCrownJO’DonovanNHER-2 signaling and inhibition in breast cancerCurr Cancer Drug Targets20099341943819442060
   PubMed Web of Science ®Google Scholar
• ChoHSMasonKRamyarKXStructure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature2003421692475676012610629
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• JunttilaTTAkitaRWParsonsKLigand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Cancer Cell200915542944019411071
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNBreast Cancer International Research GroupAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831J Clin Oncol201432333744375225332249
   PubMed Web of Science ®Google Scholar
• GoldhirschAGelberRDPiccart-GebhartMJHerceptin Adjuvant (HERA) Trial Study Team2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialLancet201338298971021102823871490
   PubMed Web of Science ®Google Scholar
• TheryJCSpanoJPAzriaDRaymondEPenault LlorcaFResistance to human epidermal growth factor receptor type 2-targeted therapiesEur J Cancer201450589290124462377
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcañaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• GarrettJTSuttonCRKubaMGCookRSArteagaCLDual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 functionClin Cancer Res201319361061923224399
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoSA phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerAnn Oncol20081961068107418283035
   PubMed Web of Science ®Google Scholar
• BarokMJoensuuHIsolaJTrastuzumab emtansine: mechanisms of action and drug resistanceBreast Cancer Res201416220924887180
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol20102881301130720142587
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJTrastuzumab: triumphs and tribulationsOncogene200726253637364317530017
   PubMed Web of Science ®Google Scholar
• XiaWGerardCMLiuLBaudsonNMOryTLSpectorNLCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsOncogene200524416213622116091755
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• ScaltritiMVermaCGuzmanMLapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene200928680381419060928
   PubMed Web of Science ®Google Scholar
• ArpinoGGutierrezCWeissHTreatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapyJ Natl Cancer Inst200799969470517470737
   PubMedGoogle Scholar
• RimawiMFWiechmannLSWangYCReduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsClin Cancer Res20111761351136121138857
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol20102871124113020124187
   PubMed Web of Science ®Google Scholar
• SwainSMBaselgaJKimSBCLEOPATRA Study GroupPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Engl J Med2015372872473425693012
   PubMed Web of Science ®Google Scholar
• MieogJSvan der HageJAvan de VeldeCJPreoperative chemotherapy for women with operable breast cancer [review]Cochrane Database Syst Rev20072CD00500217443564
   PubMed Web of Science ®Google Scholar
• MauriDPavlidisNIoannidisJPNeoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysisJ Natl Cancer Inst200597318819415687361
   PubMedGoogle Scholar
• UntchMFaschingPAKonecnyGEPathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groupsJ Clin Oncol201129253351335721788566
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHNeoALTTO Study TeamLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• CriscitielloCAzimHAJrAgbor-TarhDFactors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trialAnn Oncol20132481980198523567146
   PubMed Web of Science ®Google Scholar
• de AzambujaEHolmesAPPiccart-GebhartMLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseLancet Oncol201415101137114625130998
   PubMed Web of Science ®Google Scholar
• GuarneriVFrassoldatiABottiniAPreoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyJ Clin Oncol201230161989199522493419
   PubMed Web of Science ®Google Scholar
• RobidouxATangGRastogiPLapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialLancet Oncol201314121183119224095300
   PubMed Web of Science ®Google Scholar
• CareyLABerryDAOllilaDClinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancerJ Clin Oncol20133115 Suppl500
   Web of Science ®Google Scholar
• Piccart-GebhartMJHolmesAPBaselgaJFirst results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)J Clin Oncol20143215 Suppl Abstract LBA4
   Web of Science ®Google Scholar
• HurvitzSMillerJMDichmannRFinal analysis of a phase II 3-arm, randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2 + breast cancer (TRIO-US B07)Cancer Res20137324 Suppl Abstract S1–S02
   Google Scholar
• HolmesFANagarwalaYMEspinaVACorrelation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapyJ Clin Oncol20112915 Suppl506
   Web of Science ®Google Scholar
• RimawiMFMayerIAForeroAMulticenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006J Clin Oncol201331141726173123569315
   PubMed Web of Science ®Google Scholar
• HicksMMacraeERAbdel-RasoulMNeoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trialsOncologist201520433734325732265
   PubMed Web of Science ®Google Scholar
• SunJChenCYaoXSunSLapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trialsOncol Lett2015931351135825663912
   PubMed Web of Science ®Google Scholar
• AzimHAJrAgbor-TarhDBradburyIPattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialJ Clin Oncol201331364504451124248687
   PubMed Web of Science ®Google Scholar
• LiuHWuYLvTSkin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisKuwanoMPLoS ONE201381e5512823383079
   PubMed Web of Science ®Google Scholar
• BurtnessBGoldwasserMAFloodWPhase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol2005233486465416314626
   PubMed Web of Science ®Google Scholar
  ErratumJ Clin Oncol2006244724
   Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHFive-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P)J Clin Oncol20153315 Suppl505
   Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [database on the Internet]I-SPY 2 TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancerBethesda, MDUS National Institutes of Health2009 Available from: http://www.ClinicalTrials.gov/show/NCT01042379Accessed May 1, 2015
   Google Scholar
• ParkJWLiuMCYeeDNeratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 trialCancer Res20147419 Suppl Abstract CT227
   Web of Science ®Google Scholar
• RugoHSOlopadeODeMicheleAVeliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 trialCancer Res20137324 Suppl Abstract S5–S02
   PubMedGoogle Scholar
• JoensuuHDual targeting of HER2 with lapatinib and trastuzumabLancet Oncol201415101050105225130997
   PubMed Web of Science ®Google Scholar
• CareyLABarryWTPitcherBAlliance for Clinical Trials in OncologyGene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa)J Clin Oncol20143215 Suppl506
   Web of Science ®Google Scholar
• ScaltritiMNuciforoPBradburyIHigh HER2 expression correlates with response to the combination of lapatinib and trastuzumabClin Cancer Res201521356957625467182
   PubMed Web of Science ®Google Scholar
• ShiYHuangWTanYA novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissueDiagn Mol Pathol2009181112119214113
   PubMedGoogle Scholar
• ArribasJBaselgaJPedersenKParra-PalauJLp95HER2 and breast cancerCancer Res20117151515151921343397
   PubMed Web of Science ®Google Scholar
• PedersenKAngeliniPDLaosSA naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasisMol Cell Biol200929123319333119364815
   PubMed Web of Science ®Google Scholar
• Parra-PalauJLPedersenKPegVA major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancersCancer Res201070218537854620978202
   PubMed Web of Science ®Google Scholar
• LoiblSBrueyJVon MinckwitzGValidation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant Gepar-Quattro studyJ Clin Oncol20112915 Suppl530
   Web of Science ®Google Scholar
• MajewskiIJNuciforoPMittempergherLPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerJ Clin Oncol201533121334133925559818
   PubMed Web of Science ®Google Scholar
• DaveBMigliaccioIGutierrezMCLoss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersJ Clin Oncol201129216617321135276
   PubMed Web of Science ®Google Scholar
• GuarneriVDieciMVCarbogninLActivity of neoadjuvant lapatinib (L) plus trastuzumab (T) for early breast cancer (EBC) according to PIK3CA mutations: pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trialsAnn Oncol201425Suppl 4iv85
   Google Scholar
• PerezEADueckACMcCulloughAEImpact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialJ Clin Oncol201331172115212223650412
   PubMed Web of Science ®Google Scholar
• CristofanilliMBuddGTEllisMJCirculating tumor cells, disease progression, and survival in metastatic breast cancerN Engl J Med2004351878179115317891
   PubMed Web of Science ®Google Scholar
• RiethdorfSMüllerVZhangLDetection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trialClin Cancer Res20101692634264520406831
   PubMed Web of Science ®Google Scholar
• AzimHAJrRothéFAuraCMCirculating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trialBreast20132261060106524060577
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov [database on the Internet]A study of pertuzumab in addition to chemotherapy and herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast cancerBethesda, MDUS National Institutes of Health2011 Available from: http://www.ClinicalTrials.gov/show/NCT01358877Accessed May 1, 2015
   Google Scholar
• DangCLinNMoyBDose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaJ Clin Oncol201028182982298820479410
   PubMed Web of Science ®Google Scholar
• Moreno-AspitiaADueckACGhanem-CañeteIRC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancerBreast Cancer Res Treat2013138242743523479422
   PubMed Web of Science ®Google Scholar
• Perjetacom [database on the Internet]Neoadjuvant breast cancer treatment: Tryphaena trial overviewBasel, SwitzerlandHoffman-La Roche Ltd2015 Available from: http://www.perjeta.com/hcp/neoadjuvant/tryphaena;jsessionid=C9DC7FA332D52237F59F3D2D255C52B2.gxe501b-m2Accessed May 1, 2015
   Google Scholar
• LenihanDSuterTBrammerMNeateCRossGBaselgaJPooled analysis of cardiac safety in patients with cancer treated with pertuzumabAnn Oncol201223379180021665955
   PubMed Web of Science ®Google Scholar
• ValachisANearchouAPolyzosNPLindPCardiac toxicity in breast cancer patients treated with dual HER2 blockadeInt J Cancer201313392245225223629633
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMBlohmerJUDefinition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesJ Clin Oncol201230151796180422508812
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [webpage on the Internet]Guidance for Industry: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval 2014White Oak, MDUS Food and Drug Administration2014 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdfAccessed May 1, 2015
   Google Scholar
• ProwellTMPazdurRPathological complete response and accelerated drug approval in early breast cancerN Engl J Med2012366262438244122646508
   PubMed Web of Science ®Google Scholar
• GradisharWJAndersonBOBalassanianRBreast cancer version 2. 2015J Natl Compr Canc Netw201513444847525870381
   PubMed Web of Science ®Google Scholar
• EllisPABarriosCHEiermannWPhase III, randomized study of trastuzumab emtansine (T-DM1) {+/−} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE studyJ Clin Oncol20153315 Suppl507
   Web of Science ®Google Scholar
• HofmannDNitzUGluzOWSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trialTrials20131426123958221
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• BriaECarbogninLFurlanettoJImpact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trialsCancer Treat Rev201440784785624877987
   PubMed Web of Science ®Google Scholar